Direct-to-consumer offers for free and discounted medications on the internet: A content analysis of "e-samples"

Archives of Internal Medicine

Volumn 169, Issue 21, 2009, Pages 2024-2030

  Weppner, William G ^a   Hollon, Matthew F ^a   Chew, Lisa D ^a   Larson, Eric B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; AMPHETAMINE; ATORVASTATIN; CARVEDILOL; CELECOXIB; CLOPIDOGREL; CONJUGATED ESTROGEN; COREG CR; DIGITEK; DIGOXIN; DROSPIRENONE PLUS ETHINYLESTRADIOL; DULOXETINE; ESCITALOPRAM; ESOMEPRAZOLE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; INSULIN GLARGINE; KLOR CON; LAMOTRIGINE; LANSOPRAZOLE; LATANOPROST; LEVOFLOXACIN; LEVOTHYROXINE SODIUM; LISDEXAMFETAMINE; LOSARTAN POTASSIUM; METHYLPHENIDATE; METOPROLOL SUCCINATE; MOMETASONE FUROATE; MONTELUKAST; ORTHO TRI CYCLENLO; PANTOPRAZOLE; PIOGLITAZONE; POTASSIUM CHLORIDE; PREGABALIN; PROCATEROL; QUETIAPINE; RAMIPRIL; RISEDRONIC ACID; RISPERIDONE; ROSIGLITAZONE; ROSUVASTATIN; SILDENAFIL; TAMSULOSIN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALSARTAN; VARENICLINE; VENLAFAXINE; ZOLPIDEM TARTRATE;

CONSUMER; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNET; NOTE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNITED STATES;

ADVERTISING AS TOPIC; CONSUMER SATISFACTION; DRUG COSTS; DRUG INDUSTRY; GUIDELINES AS TOPIC; HUMANS; INTERNET; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73249121189     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.397     Document Type: Note

References (32)

1. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7):673-681.
2. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999;281(4):380-382.
3. Hollon MF. Direct-to-consumer advertising: a haphazard approach to health promotion. JAMA. 2005;293(16):2030-2033.
4. American College of Physicians. Direct-to-Consumer Prescription Drug Advertising. Philadelphia, PA: American College of Physicians; 2006.
5. Division of Drug Marketing Advertising and Communications. Guidance for Industry: Consumer-Directed Broadcast Advertisements. Rockville, MD: Food and Drug Administration; 1999.
6. Fox S. Prescription Drugs Online. Washington, DC: Pew Internet&American Life Project; October 10, 2004.
7. Elkin N. How America Searches: Health and Wellness. Princeton, NJ: Opinion Research Corporation; 2008.
8. Drug reps must embrace technology to avoid missing sales opportunities. Pharmaceutical Business Review Web page. March 15, 2006. http://www. pharmaceutical-business-review.com/comment/drug-reps-must-embrace -technology-to-avoid-missing-sales-opportunities-comment. Accessed June 2008.
9. Verispan VONA. Top 200 brand drugs by units in 2007. March 2008. http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard/drugtopics/ 072008/491207/article.pdf. Accessed June 2008.
10. Center for Drug Evaluation and Research. Drugs@FDA [database online]. Silver Spring, MD: Center for Drug Evaluation and Research, Food and Drug Administration. http: //www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/. Accessed March 2009.
11. US Pharmacopeia. Model guidelines and formulary key drug types version 4.0. 2008. http: //www.usp.org/hqi/mmg/revisions.html. Accessed June 25, 2009.
12. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising, 1989-1998: a content analysis of conditions, targets, inducements, and appeals. J Fam Pract. 2000;49(4):329-335.
13. McKesson Corporation. McKesson patient relationship solutions: trialscript difference. http: //sites.mckesson.com/mprs/solutions/trialscript- difference.shtml. Accessed February 2, 2009.
14. Schwartz KL, Roe T, Northrup J, Meza J, Seifeldin R, Neale AV. Family medicine patients' use of the Internet for health information: a MetroNet Study. J Am Board Fam Med. 2006;19(1):39-45.
15. Rideout V. e-Health and the Elderly: How Seniors Use the Internet for Health Information. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2005.
16. Fox S. Older Americans and the Internet. Washington, DC: Pew Internet & American Life Project; March 25, 2004.
17. Miesner AR, Allen DP, Koenigsfeld CF, Wall GC. Effect of sample medication restrictions on prescribing at a private clinic. Arch Intern Med. 2009;169(13):1241-1242.
18. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15(7):478-483.
19. Symm B, Averitt M, Forjuoh SN, Preece C. Effects of using free sample medications on the prescribing practices of family physicians. J Am Board Fam Med. 2006;19(5):443-449.
20. Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? a randomized trial. Am J Med. 2005;118(8):881-884.
21. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995-2002.
22. Gilbody S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care. 2005;14(4):246-250.
23. Mansfield PR, Mintzes B, Richards D, Toop L. Direct to consumer advertising. BMJ. 2005;330(7481):5-6.
24. Pharmaceutical Research and Manufacturers of America. PhRMA guiding principles on direct to consumer advertisements about prescription medicines. December 10, 2008. http://www.phrma.org/news-room/press-releases/americas -pharmaceutical-research-companies-enhance-voluntary-guidelines-on-dtc- advertising/. Accessed August 18, 2009.
25. Food and Drug Administration. Guidance for industry presenting risk information in prescription drug and medical device promotion: draft guidance. May 2009. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM155480.pdf. Accessed June 2009.
26. Food and Drug Administration. Letter to GlaxoSmithKline. March 26, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ EnforcementActivitiesbyFDA/ WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166243. pdf. Accessed April 2009.
27. Bodenheimer T, Grumbach K. Electronic technology: a spark to revitalize primary care? JAMA. 2003;290(2):259-264.
28. Tang PC, Lee TH. Your doctor's office or the Internet? two paths to personal health records. N Engl J Med. 2009;360(13):1276-1278.
29. Harris Interactive. Patient/physician online communication: Many patients want it, would pay for it, and it would influence their choice of doctors and health plans. April 10, 2002. http: //www.harrisinteractive.com/news/ newsletters/healthnews/HI-HealthCareNews2002Vol2-Iss08.pdf. Accessed September 16, 2008.
30. Iizuka T. What explains the use of direct to consumer advertising of prescription drugs? J Ind Econ. 2004;52(3):349-379.
31. Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG. Generic entry, reformulations and promotion of SSRIs in the US. Pharmacoeconomics. 2008;26(7):603-616.
32. World Health Organization. Criteria for medicinal drug promotion. 1988. http://apps.who.int/medicinedocs/en/d/Jwhozip08e/4.html#Jwhozip08e.4. Accessed July 2009.